GLP-1 'beginner mistakes': what the science says vs. TikTok

What did @_life_with_kaitlyn actually say?

Honestly? Not much. The transcript is essentially a series of repeated sound bites, "Action! Action! Action! Action!" layered over what appears to be a reaction format. There are no specific medical claims, no dosing advice, no named side effects, and no concrete guidance about GLP-1 medications anywhere in the spoken content.

The caption promises "mistakes when starting a GLP1," which implies practical, potentially medical information for the 33,600 people who watched it. The hashtags include #semaglutide, #tirzepitide, and #obesitymedicine, which signals to viewers that medically relevant content is coming. But the actual audio delivers none of that. What viewers got was a meme-style audio clip that tells them they "fucked around and found out" without specifying what they did wrong, what the consequences are, or what to do differently.

This is a pattern worth naming: the caption and hashtag stack does the medical credibility work while the video itself remains un-fact-checkable because it never actually says anything.

Does the science back this up?

There is nothing to evaluate scientifically here. No claim was made. The implicit suggestion, that people starting GLP-1s make predictable mistakes, is actually well-supported by clinical literature. But this video does not deliver that information.

What we do know from the research: GLP-1 receptor agonists like semaglutide and tirzepatide carry real, documented side effect profiles that catch new users off guard. Wilding et al. (2021, NEJM) noted nausea, vomiting, and diarrhea as the most common adverse events in the STEP 1 trial, affecting up to 44% of participants on semaglutide. Frías et al. (2021, NEJM) found similar gastrointestinal patterns with tirzepatide in the SURPASS-2 trial. Muscle mass loss during rapid weight loss on GLP-1s is another documented concern, with Bikou et al. (2023, Nutrients) flagging the importance of protein intake and resistance training during treatment. These are real "mistakes" people make. Eating too little protein, skipping fiber, not adjusting injection timing to manage nausea. None of this is in the video.

What did they get wrong (or right)?

Getting something wrong requires actually saying something. This video does neither incorrectly nor correctly. It gestures at a topic and then retreats into audio meme territory.

The caption framing is the real issue. Tagging a video with #obesitymedicine and #semaglutide creates an implied authority. Viewers searching those tags are often newly prescribed patients trying to figure out what to expect. They deserve actual information. What they got was a reaction clip that tells them consequences exist without explaining what those consequences are, why they happen, or how to reduce them.

To give credit where it is due: the tone of "you're dealing with the consequences of your actions" is not medically harmful. It does not recommend a dose, does not claim GLP-1s cure anything, and does not suggest compounded versions are equivalent to brand-name drugs. It is just... empty. In a space full of genuinely dangerous GLP-1 misinformation, empty is not the worst outcome. But empty content with medical hashtags still directs viewer attention away from sources that could actually help them.

What should you actually know?

If you are starting a GLP-1 medication and you searched this hashtag hoping to avoid common mistakes, here is what the research actually supports.

• Gastrointestinal side effects are the most common reason people discontinue. Starting at the lowest dose and titrating slowly reduces severity. Davies et al. (2021, Lancet) found structured titration significantly improved tolerability in clinical settings.
• Eating high-fat or large meals while on GLP-1s amplifies nausea. Smaller, lower-fat meals are consistently recommended in clinical practice guidelines from the American Diabetes Association (2024 Standards of Care).
• Muscle mass loss is a real concern during GLP-1-driven weight loss. Adequate protein intake (at minimum 1.2g per kg of body weight daily) and resistance exercise are supported by current evidence as protective. Bikou et al. (2023, Nutrients) specifically examined this in GLP-1 populations.
• Hydration matters more than most people starting these medications expect. Reduced appetite can suppress thirst signaling, and dehydration compounds nausea.
• Injection site rotation is not optional. Lipohypertrophy from repeated injection in the same spot reduces drug absorption, per FDA prescribing guidance for semaglutide.

These are the mistakes worth a TikTok. Not a sound effect telling you that you already made them.